Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

Ovid Technologies (Wolters Kluwer Health) - Tập 102 Số 22 - Trang 2700-2706 - 2000
Faı̈ez Zannad1, François Alla1, B. Dousset1, A.J. Pérez Pérez1, Bertram Pitt1
1From the Centre d’Investigation Clinique INSERM-CHU (F.Z., F.A.) and the Laboratory of Biochemistry (B.D.), Centre Hospitalier Universitaire, University Henri Poincaré, Nancy, France; Searle Monsanto (A.P), Skokie, Ill; and the Department of Internal Medicine (B.P.), Division of Cardiology, University of Michigan, Ann Arbor.

Tóm tắt

Background —In congestive heart failure (CHF), extracellular matrix turnover is a major determinant of cardiac remodeling. It has been suggested that spironolactone may decrease cardiac fibrosis. We investigated the interactions between serum markers of cardiac fibrosis and the effect of spironolactone on outcome in patients with CHF. Methods and Results —A sample of 261 patients from the Randomized Aldactone Evaluation Study (RALES) were randomized to placebo or spironolactone (12.5 to 50 mg daily). Serum procollagen type I carboxy-terminal peptide, procollagen type I amino-terminal peptide, and procollagen type III amino-terminal peptide (PIIINP) were assessed at baseline and at 6 months. Baseline PIIINP >3.85 μg/L was associated with an increased risk of death (relative risk [RR] 2.36, 95% CI 1.34 to 4.18) and of death+hospitalization (RR 1.83, 95% CI 1.18 to 2.83). At 6 months, markers decreased in the spironolactone group but remained unchanged in the placebo group. The spironolactone effect on outcome was significant only in patients with above-median baseline levels of markers. RR (95% CI) values for death among patients receiving spironolactone were 0.44 (0.26 to 0.75) and 1.11 (0.66 to 1.88) in subgroups of PIIINP levels above and below the median, respectively. Similarly, RR (95% CI) values for death+hospitalization among patients receiving spironolactone were 0.45 (0.29 to 0.71) and 0.85 (0.55 to 1.33), respectively. Conclusions —In patients with CHF, high baseline serum levels of markers of cardiac fibrosis synthesis are significantly associated with poor outcome and decrease during spironolactone therapy. The benefit from spironolactone was associated with higher levels of collagen synthesis markers. These results suggest that limitation of the excessive extracellular matrix turnover may be one of the various extrarenal mechanisms contributing to the beneficial effect of spironolactone in patients with CHF.

Từ khóa


Tài liệu tham khảo

10.1056/NEJM199909023411001

10.1056/NEJM199909023411009

10.1016/0002-9149(93)90132-V

Zannad F. Aldosterone and heart failure. Eur Heart J. 1995;16(suppl):98–102.

10.1006/jmcc.1993.1066

10.1358/mf.1999.21.3.534832

Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res. 2000;1994:1863–1867.

10.1152/physrev.1999.79.1.215

Weber KT. Monitoring tissue repair and fibrosis from a distance. Circulation. 1997;96:2488–2492.

10.1161/circ.98.6.535

10.1161/circ.96.8.2565

10.1136/hrt.78.5.505

10.1016/S0002-9149(99)80251-3

10.1016/S0002-9149(99)80686-9

10.1161/circ.91.5.1450

Querejeta R, Varo N, Lopez B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;201:1729–1735.

10.1016/S0009-9120(97)00097-0

10.1093/clinchem/42.6.947

10.1093/clinchem/36.7.1328

10.1093/clinchem/34.4.715

10.1016/S0008-6363(97)00072-2

10.1161/circ.93.5.1026

10.1253/jcj.49.171

Whittaker P, Boughner DR, Kloner RA. Analysis of healing after myocardial infarction using polarized light microscopy. Am J Pathol. 1989;134:879–893.

Risteli J Risteli L. Analysing connective tissue metabolites in human serum: biochemical physiological and methodological aspects. J Hepatol. 1995;22(suppl 2):77–81.

10.1161/circ.81.1.2297848

10.1161/circ.83.6.2040049

10.1016/S0008-6363(00)00032-8

Willems IE, Havenith MG, De Mey JG, et al. The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am J Pathol. 1994;145:868–875.

Cleutjens JP, Verluyten MJ, Smiths JF, et al. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 1995;147:325–338.

Zannad F, Briancon S, Juilliere Y, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study: Epidémiologie de l’Insuffisance Cardiaque Avancée en Lorraine. J Am Coll Cardiol. 1999;34:734–742.

10.1093/oxfordjournals.eurheartj.a015156

10.1096/fasebj.5.8.1850705

10.1016/0163-7258(93)90074-N

10.1016/S0022-2828(95)90359-3

10.1161/01.hyp.24.1.30

10.1172/JCI117269

Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med. 1992;120:893–901.

10.1016/S0008-6363(97)00091-6

10.1007/BF00180074

Thông tin
Thông tin xuất bản

Ovid Technologies (Wolters Kluwer Health)

Tập 102 Số 22

2700-2706

Thông tin tác giả